BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» HK growling: Wary plotter Astrazeneca ticks box on safety data pre-$2.7B ZS Pharma buy
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
HK growling: Wary plotter Astrazeneca ticks box on safety data pre-$2.7B ZS Pharma buy
Nov. 9, 2015
By
Randy Osborne
No Comments
With the hyperkalemia (HK) space hotter after Astrazeneca plc's $2.7 billion takeover of ZS Pharma Inc. to get the approval-ready ZS-9, eyes of handicappers turned to long-term safety data due at a scientific meeting over the weekend.
BioWorld